The SC route also exposes to an increased risk of neutralizing autoantibodies against IFN-β, which could compromise the efficacy of IFN-β-based therapeutics as previously described in patients with multiple sclerosis (Sominanda et al., 2010). Here, IFNB1 is linked to multiple sclerosis.